NIKE Stock And 2 Other Great Dividend Stocks

The bond market has shifted into a world of 5% yields, and income investors suddenly have real competition for their cash. When government bonds pay more, weaker dividends start to look fragile. The opportunity sits with businesses that keep paying you through thick and thin. This article highlights three high-yield stocks where dividends above 3% are supported by coverage, growth and stability for investors who want to receive income while they wait.

The three stocks covered below are only a small sample of what income-focused investors can consider, as the full screen surfaces 2,264 more companies with similarly robust dividend stories that are not unpacked here. To go straight to the full list and quickly identify, analyze and prioritize your next income ideas, head into the Dividend Powerhouses (3%+ Yield) screener.

Overview: NIKE is a global sportswear business that designs, makes and sells athletic footwear, apparel and equipment, funding a sizable recurring dividend from its broad footwear and clothing sales to consumers and wholesale partners.

Operations: NIKE generates about US$46.4b in annual revenue, led by NIKE Brand North America at US$20.5b and Europe, Middle East & Africa at US$12.6b, with roughly US$20.4b from the United States and US$26.0b from the rest of the world.

Market Cap: US$53.0b

NIKE fits this high-yield dividend screen because its 4.59% payout is backed by a global footwear and apparel engine that still produces cash, even as questions build around how durable that cash generation will be through a drawn-out turnaround.

“However, there are some risks for the company, represented by the High uncertainty rating, showing that Nike, despite having a history of success, needs to keep reinventing itself by providing, as always, great products to its clients.”

What matters now is how one unresolved pressure on NIKE’s cash generation shapes the strength and direction of future payouts.

That pressure on NIKE’s cash engine is exactly what the full narrative for NIKE unpacks. It reveals how reinvention, brand strength and capital returns could still accelerate from here.

Overview: Accenture helps large organisations run and improve everyday functions like finance, HR and IT through long-term consulting and outsourcing contracts that underpin its dividend profile.

Operations: Accenture generates about US$22.3b from Products clients, US$14.9b from Health & Public Service, US$13.8b from Financial Services, US$12.4b from Communications, Media & Technology and US$9.8b from Resources, with revenue reported across regions that include Asia Pacific at roughly US$10.6b.

Market Cap: US$107.8b

Accenture matters for income-focused investors because those global outsourcing and managed services contracts often run for years. This can translate into steadier cash flow backing its 3%+ yield.

“The market is asking whether Accenture can convert AI from a threat into a growth engine.”

What investors are really waiting to see is how that AI push feeds into the next leg of recurring demand and cash generation.

That next chapter starts with how Accenture leans into AI, which is exactly what the full narrative for Accenture breaks down. It also covers where demand acceleration or risk may be hiding.

Overview: Novo Nordisk develops diabetes and obesity medicines that generate recurring cash flow supporting its 3%+ dividend, alongside smaller rare disease treatments and drug delivery devices.

Operations: Novo Nordisk generates about DKK 309b from Diabetes and Obesity Care and DKK 20b from Rare Disease therapies and related products.

Market Cap: DKK1,118.98b

Novo Nordisk matters in this dividend screen because its diabetes and obesity treatments underpin a sizeable 3%+ yield backed by a long-running cash engine, even as the business reinvests heavily for its next phase of growth.

“In recent years, the company has been riding an extraordinary wave of success thanks to the global weight-loss drug boom. Its GLP-1-based drug semaglutide, originally developed for type 2 diabetes, turned out to be incredibly effective for weight loss.”

What really shapes the long term dividend story now is how one emerging source of competitive and pricing pressure plays out against that cash flow.

That pressure point is exactly what the full narrative for Novo Nordisk unpacks, separating short term hype from longer term cash strength and emerging risks.

Curious About Alternatives You Might Be Missing?

Fresh dividend ideas do not stay quiet for long. Breakout yields and under the radar cash machines get caught quickly. Scan what is flying now and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com